AR072697A1 - PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDER - Google Patents

PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDER

Info

Publication number
AR072697A1
AR072697A1 ARP090102523A ARP090102523A AR072697A1 AR 072697 A1 AR072697 A1 AR 072697A1 AR P090102523 A ARP090102523 A AR P090102523A AR P090102523 A ARP090102523 A AR P090102523A AR 072697 A1 AR072697 A1 AR 072697A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
heterocyclyl
cycloalkyl
aryl
Prior art date
Application number
ARP090102523A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR072697A1 publication Critical patent/AR072697A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo; donde R1 representa R7C(O); R2 representa alquiltio C1-3 insustituido o hidroxialquil C1-3 insustituido; R7 representa alquil C1-3 opcionalmente interrumpido por oxígeno, y/o opcionalmente sustituido por OH, arilo, cicloalquil C3-6, heterociclil o uno o más átomos de halogeno (F, Cl, Br, l); además R7 representa cicloalquil C3-6, hidroxialquil C1-12, aril o heterociclil; R14 representa H, OH con la condicion de que el grupo OH debe estar al menos 2 átomos de carbono separado de cualquier heteroátomo en el sistema de anillo/anillo B, alquil C1-8 opcionalmente interrumpido por oxígeno y/o opcionalmente sustituido por uno o más OH, COOH y COORe donde Re representa aril, cicloalquil C3-6, heterociclil o alquil C1-8 opcionalmente sustituido por uno o más átomo(s) de halogeno (F, CI, Br, l), OH, aril, cicloalquil C3-6 y heterociclil; además R14 representa aril, arilalquil C1-8, arilalcoxi C1-3, heterociclil, un átomo de halogeno (F, CI, Br, l), cicloalquil C3-6, cicloalquil C3-6alcoxi C1-8, hidroxialquil C1-8, alcoxi C1-8, cicloalcoxi C3-6, alquilsulfinil C1-8, alquilsulfonil C1-8, alquiltio C1-8, cicloalquiltio C3-6, o un grupo de la formula NRa(14)Rb(14) en la cual Ra(14) y Rb(14) independientemente representan H, alquil C1-8, alquil-C(O) C1-8, alcoxi-C(O) C1-8 o Ra(14) y Rb(14) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; Rc es un enlace directo o representa un grupo alquileno C1-4 insustituido o monosustituido o polisustituido, donde cualesquiera sustituyentes cada uno individual e independientemente son seleccionados de alquil C1-4, alcoxil C1-4, oxi-alquil C1-4, alquenil C2-4, alquinil C2-4, cicloalquil C3-6, carboxil, carboxialquil C1-4, aril, heterociclil, ciano, halogeno (F, Cl, Br, l), hidroxil, NRa(Rc)Rb(Rc) en la cual Ra(Rc) y Rb(Rc) individual e independientemente uno del otro representan hidrogeno, alquil C1-4 o Ra(Rc) y Rb(Rc) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; además Rc representa imino (-NH-), imino N sustituido (-NR19-), alquilenoimino C1-4 o alquilenoimino C1-4 N-sustituido (-N(R19)-alquileno C1-4) donde los grupos alquileno mencionados son insustituidos o monosustituidos o polisustituidos con cualesquiera sustituyentes de acuerdo con lo anterior; R19 representa H o alquil C1-4; Rd representa alquil C1-12, cicloalquil C3-8, aril o heterociclil, y cualquiera de estos grupos opcionalmente sustituido con uno o más átomos de halogeno (F, Cl, Br, l) o átomos de halogeno mezclados y/o uno o más de los siguientes grupos, OH, CN, alquil C1-12, alcoxi-C(O) C1-12, alcoxi C1-12, alquil C1-12 sustituido con halogeno, cicloalquil C3-6, aril, heterociclil, alquilsulfinil C1-12, alquilsulfonil C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinil, arilsulfonil, ariltio, arilalquiltio C1-12, arilaIquiIsulfinil C1-12, ariIalquilsulfonil C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinil C1-12, heterociclilalquilsulfonil C1-12, cicloalquil C3-6alquiltio C1-12, cicloalquil C3-6alquilsulfinil C1-12, cicloalquil C3-6alquilsulfonil C1-12 o un grupo de la formula NRa(Rd)Rb(Rd) en la cual Ra(Rd) y Rb(Rd) independientemente representan H, alquil C1-12, alquil-C(O) C1-12 o Ra(Rd) y Rb(Rd) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; X representa un enlace simple, imino (-NH-), metileno (-CH2-), iminometileno (-CH2-NH-) donde el carbono está conectado al sistema de anillo/anillo B, metilenoimino (-NH-CH2-) donde el nitrogeno está conectado al sistema de anillo/anillo B y cualquier carbono y/o nitrogeno en estos grupos puede ser opcionalmente sustituido con alquil C1-6; además X puede representar un grupo (-CH2-)n donde n = 2-6, el cual opcionalmente es insaturado y/o sustituido por uno o más sustituyentes escogidos entre halogeno, hidroxil o alquil C1-6; y B es un sistema de anillo/anillo heterocíclico de 4 a 11 miembros, monocíclico o bicíclico que comprende uno o más nitrogenos y opcionalmente uno e más átomos seleccionados de oxígeno o azufre, dicho nitrogeno es conectado al anillo de piridina (de acuerdo con la formula (1)) y además el sistema de anillo/anillo B es conectado a X en otra de sus posiciones; el sustituyente R14 es conectado al sistema de anillo/anillo B de manera tal que no se forman compuestos de amonio cuaternario (por esta conexion).Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof; where R1 represents R7C (O); R2 represents unsubstituted C1-3 alkylthio or unsubstituted C1-3 hydroxyalkyl; R7 represents C1-3 alkyl optionally interrupted by oxygen, and / or optionally substituted by OH, aryl, C3-6 cycloalkyl, heterocyclyl or one or more halogen atoms (F, Cl, Br, l); R7 also represents C3-6 cycloalkyl, C1-12 hydroxyalkyl, aryl or heterocyclyl; R14 represents H, OH with the proviso that the OH group must be at least 2 carbon atoms separated from any heteroatom in the ring / ring B system, C1-8 alkyl optionally interrupted by oxygen and / or optionally substituted by one or plus OH, COOH and COORe where Re represents aryl, C3-6 cycloalkyl, heterocyclyl or C1-8 alkyl optionally substituted by one or more halogen atom (s) (F, CI, Br, l), OH, aryl, C3 cycloalkyl -6 and heterocyclyl; R14 also represents aryl, C1-8 arylalkyl, C1-3 arylalkoxy, heterocyclyl, a halogen atom (F, CI, Br, l), C3-6 cycloalkyl, C3-6alkoxy C1-8 alkoxy, C1-8 hydroxyalkyl, alkoxy C1-8, C3-6 cycloalkoxy, C1-8 alkylsulfinyl, C1-8 alkylsulfonyl, C1-8 alkylthio, C3-6 cycloalkylthio, or a group of the formula NRa (14) Rb (14) in which Ra (14) and Rb (14) independently represent H, C1-8 alkyl, C-alkyl (O) C1-8, alkoxy-C (O) C1-8 or Ra (14) and Rb (14) together with the nitrogen atom represent piperidine, pyrrolidine, azetidine or aziridine; Rc is a direct bond or represents an unsubstituted or monosubstituted or polysubstituted C1-4 alkylene group, where any substituents each individually and independently are selected from C1-4 alkyl, C1-4 alkoxy, C1-4 oxy-alkyl, C2 alkenyl 4, C2-4 alkynyl, C3-6 cycloalkyl, carboxy, C1-4 carboxyalkyl, aryl, heterocyclyl, cyano, halogen (F, Cl, Br, l), hydroxyl, NRa (Rc) Rb (Rc) in which Ra (Rc) and Rb (Rc) individually and independently of each other represent hydrogen, C1-4 alkyl or Ra (Rc) and Rb (Rc) together with the nitrogen atom represent piperidine, pyrrolidine, azetidine or aziridine; Rc also represents imino (-NH-), imino N substituted (-NR19-), C1-4 alkyleneimino or C1-4 N-substituted alkyleneimino (-N (R19) -C 1-4 alkylene) where the mentioned alkylene groups are unsubstituted or monosubstituted or polysubstituted with any substituents in accordance with the foregoing; R19 represents H or C1-4 alkyl; Rd represents C1-12 alkyl, C3-8 cycloalkyl, aryl or heterocyclyl, and any of these groups optionally substituted with one or more halogen atoms (F, Cl, Br, l) or mixed halogen atoms and / or one or more of the following groups, OH, CN, C1-12 alkyl, C-C (O) C1-12 alkoxy, C1-12 alkoxy, halogen substituted C1-12 alkyl, C3-6 cycloalkyl, aryl, heterocyclyl, C1-12 alkylsulfinyl , C1-12 alkylsulfonyl, C1-12 alkylthio, C3-6 cycloalkylthio, arylsulfinyl, arylsulfonyl, arylthio, C1-12 arylalkyl, arylaIquiIsulfinyl C1-12, ariIalkylsulfonyl C1-12, heterocyclyl-alkylthio C1-12, heterocyclyl-Cyl-alkylsylfinyl-cyl-cyl-alkylsulffin 12, C3-6 cycloalkyl C1-12alkylthio, C3-6alkylcycloalkyl C1-12, cycloalkylC3-6alkyl sulfonyl C1-12 or a group of the formula NRa (Rd) Rb (Rd) in which Ra (Rd) and Rb (Rd ) independently represent H, C1-12 alkyl, C-C (O) C1-12 alkyl or Ra (Rd) and Rb (Rd) together with the nitrogen atom represent piperidine, pyrrolidine, azetidin a or aziridine; X represents a simple bond, imino (-NH-), methylene (-CH2-), iminomethylene (-CH2-NH-) where carbon is connected to the ring / ring B system, methyleneimino (-NH-CH2-) where the nitrogen is connected to the ring / ring B system and any carbon and / or nitrogen in these groups can be optionally substituted with C1-6 alkyl; X can also represent a group (-CH2-) n where n = 2-6, which is optionally unsaturated and / or substituted by one or more substituents chosen from halogen, hydroxyl or C1-6 alkyl; and B is a 4 to 11-membered, monocyclic or bicyclic heterocyclic ring / ring system comprising one or more nitrogen and optionally one and more atoms selected from oxygen or sulfur, said nitrogen is connected to the pyridine ring (according to the formula (1)) and in addition the ring / ring system B is connected to X in another of its positions; substituent R14 is connected to the ring / ring system B so that no quaternary ammonium compounds are formed (by this connection).

ARP090102523A 2008-07-07 2009-07-06 PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDER AR072697A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7848008P 2008-07-07 2008-07-07
US12201608P 2008-12-12 2008-12-12

Publications (1)

Publication Number Publication Date
AR072697A1 true AR072697A1 (en) 2010-09-15

Family

ID=41507301

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102523A AR072697A1 (en) 2008-07-07 2009-07-06 PIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF PLATQUETARY AGGREGATION DISORDER

Country Status (2)

Country Link
AR (1) AR072697A1 (en)
WO (1) WO2010005384A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039405A (en) * 2005-07-13 2008-05-07 아스트라제네카 아베 New pyridine analogues
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008004945A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline forms i and ii
WO2008004944A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline form ii
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
MX2009007429A (en) * 2007-01-12 2009-07-17 Astrazeneca Ab Pyridine compounds and their use as p2y12 antagonists.
CL2008000093A1 (en) * 2007-01-12 2008-08-22 Astrazeneca Ab COMPOUNDS DERIVED FROM PIRIDINA, INHIBITORS OF P2Y12; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF A PLAQUETARY AGREGATION DISORDER.

Also Published As

Publication number Publication date
WO2010005384A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
AR061651A1 (en) PIRIDINE ANALOGS II
AR054632A1 (en) PIRIDINE ANALOGS, COMPOSITIONS THAT CONTAIN THEM AND PROCESSES FOR THEIR PREPARATION
AR059279A1 (en) DERIVATIVES OF TRICYCLE N-HETEROARIL-CARBOXAMIDS CONTAINING A REST BENCIMIDAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR059218A1 (en) PIRIMIDINE DERIVATIVES
AR061564A1 (en) DERIVATIVES OF ISOINDOLS, PHARMACEUTICAL COMPOSITIONS AND USES
AR060605A1 (en) DERIVATIVES OF DIAZEPAN AS ANTAGONISTS OF THE CCR2 RECEIVER
AR045752A1 (en) QUINAZOLINE DERIVATIVES THAT HAVE ANTITUMORAL ACTIVITY
AR070207A1 (en) BICYCLE DERIVATIVES OF CARBOXAMIDAS AZA- BICICLICAS ITS PREPARATION AND ITS THERAPEUTIC APPLICATION
AR069480A1 (en) DERIVATIVES OF 2-AMINO-PYRIMIDINE
AR066492A1 (en) DERIVATIVES OF IMIDAZOQUINOLINE, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR THE TREATMENT OF VIRAL, BACTERIAL, ALLERGIC AND DIFFERENT TYPES OF CANCERES.
AR058381A1 (en) COMPOUNDS DERIVED FROM 2-AMINOPIRIDIN-4-ONAS AND A PHARMACEUTICAL COMPOSITION
AR070992A1 (en) DERIVATIVES OF 2-ARIL-6-FENIL-INIDAZO [1,2A] PIRIDINAS, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN DISEASES THAT INVOLVE NURLE-1 NUCLEAR RECEPTORS
AR066561A1 (en) IMIDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
PE20120031A1 (en) ARYL METHYL BENZOQUINAZOLINONE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE M1 RECEPTOR
AR060658A1 (en) DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
AR070995A1 (en) POLISUSTITUTED DERIVATIVES OF 6-HETEROARIL-IMIDAZO [1,2-A] PIRIDINA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESS OF THE SAME, INTERMEDIARIES OF SYNTHESIS AND USE OF THE SAME IN THE TREATMENT OR PREVENTION OF NURSING -1, SUCH AS ENFE
PE20130306A1 (en) MORPHOLINOPYRIMIDINES AND THEIR USE IN THERAPY
AR056197A1 (en) DERIVATIVES OF 7-METHYLIMIDAZOL [1,2-A] PIRIDIN-6-IL-8-METHYL-NONAMIDS AS INHIBITORS OF THE RENIN, PHARMACEUTICAL COMPOSTIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ARTERIAL HYPERTENSION
AR076859A1 (en) DERIVATIVES OF 1,2,4-TRIAZOLO [4,3-A] PIRIDINE POSITIVE MODULATORS OF MGLUR2 RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF NEUROLOGICAL AND SYNCHIATRIC DISORDERS.
AR043181A1 (en) HETEROCICLIL-3-SULPHONYLINDAZOLS AS LIGANDS OF 5-HYDROXYPTAMINE-6
AR053092A1 (en) COMPOUNDS DERIVED FROM PHENOXYACETIC ACID AND INTERMEDIATE SYNTHESIS COMPOUNDS
AR040048A1 (en) DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND INDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6
AR068466A1 (en) CYANOISOQUINOLINE
AR051334A1 (en) DERIVATIVES OF 2- AMIDO-4-PHENYLTIAZOL
AR069813A1 (en) DERIVATIVES OF 2- AMINO-PYRIMIDINE, A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARATION OF THE COMPOUND AND USE OF IT TO PREPARE A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure